Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAV1-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Novasep Signs €4.7m Biomanufacturing Deal with Biotech
Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Product Name : Mydicar
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : AAV1-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Sensorion and Novasep Sign Agreement
Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Product Name : OTOF-GT
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 11, 2020
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement